News

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...
GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...
GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...
GSK has carried pipeline momentum into Q1, with two new U.S. approvals as highlighted. Looking ahead, we expect three more approvals for Nucala COPD, Blenrep and depemokimab this year, with PDUFA ...
Data presented at CROI for VH184, VH499 and N6LS support development plans for ULA HIV regimens Breakthrough designation granted for GSK'227 B7H3 ADC for 2L osteosarcoma Pivotal/Phase III trials ...
GSK reported 4% year-on-year earnings growth ... Blenrep's application in second-line multiple myeloma (July 23), and depemokimab's application in severe asthma (end of the year).
Depemokimab, GSK’s long-acting, anti-interleukin (IL)-5 monoclonal antibody (mAB), is currently under review as an add-on maintenance treatment for asthma in paediatric (≥12 years old ...